Preclinical: where are we with tumor ... - Fight Prostate Ca...

Fight Prostate Cancer

2,950 members1,293 posts

Preclinical: where are we with tumor reversion?

Maxone73 profile image
3 Replies

Let's start 2025 with a post that makes us look at something that will be a revolution...it's good to start the new year with a dream.

Tumor reversion, the process of reprogramming cancer cells into normal-like cells, is emerging as a transformative approach to cancer therapy, offering a less toxic alternative to traditional treatments.

Recent breakthroughs include a 2024 study from KAIST, where researchers identified molecular switches to revert colon cancer cells through digital twin modeling, and findings from St. Jude’s Research Hospital, showing protein removal can reverse malignant cell identity in aggressive tumors like rhabdoid cancers.

Despite promising results, challenges remain, including decoding complex molecular pathways, modulating the tumor microenvironment, and scaling therapies for clinical use. Advanced tools like CRISPR, multi-omics, and AI are accelerating progress.

The potential is enormous, and AI can really help with its ability to find patterns and analyze huge amounts of data!

prostatewarriors.com/2025/0...

Written by
Maxone73 profile image
Maxone73
To view profiles and participate in discussions please or .
Read more about...
3 Replies
Broccoli24 profile image
Broccoli24

Positive news… another interesting route to keep an eye on… and other one that seems much less systemically damaging. Happy New year and THANKS for these posts.

Yzinger profile image
Yzinger

Great post Max. Has anyone here heard of a short mini series called "First in Human"?

It's really good imo. Sad too but good message I took from it. Must watch

Maxone73 profile image
Maxone73 in reply toYzinger

I will have to check it out!

Not what you're looking for?

You may also like...

Glutamine blockade to starve tumors, Using bacteria in the microbiome to attack cancer, 2 articles on finding dormant cancer cells in bone

Greetings FPC Members, First, a glutamine uptake blocker, IMD-0354, in development to starve...
NPfisherman profile image

CCR6 & CCL20 are the key drivers in prostate tumor microenvironment.

This is a very good Feb 2023 article but it’s best to scroll down to get out of the weeds to the...
KocoPr profile image

Prostate Cancer and Immunotherapy Breakout Session at the 2020 CRI Virtual Immunotherapy Patient Summit with introduction to my next post

Hello FPC members, This is a growing area of research in cancers as getting the body's immune...
NPfisherman profile image

Seminal Vesicle Invasion & Senescent tumor cells.

New study below [1]. Note: "p16 (also known as p16INK4a ...), is a protein that slows cell...
pjoshea13 profile image

Doxycycline

Bottom Line: Low-dose Doxycycline may be a useful add-on to other therapies, for a number of...
pca2004 profile image